THE USE OF METFORMIN IN WOMEN WITH POLYCYSTIC OVARY SYNDROME: A LITERATURE REVIEW

Abstract

This article aims to review the most recent and current literature regarding the use of metformin in patients diagnosed with Polycystic Ovary Syndrome (PCOS), a common endocrinopathy in women of reproductive age. Metformin has established itself as an effective therapeutic option for the syndrome, resulting in improved metabolic profiles and positive effects related to reproduction. Its use is associated with the regularization of the menstrual cycle, induction of ovulation, and improved fertility, as well as playing a significant role in reducing circulating androgens. Recent studies have investigated the combination of metformin with other agents, working synergistically, such as probiotics, dopaminergic agonists, and GLP-1 analogs, showing promising and satisfactory effects. Additionally, research on predictive response markers and their application in assisted reproduction protocols is highlighted. Metformin also presents a satisfactory safety profile during pregnancy with no serious adverse effects. These advances reinforce metformin as a relevant and promising therapeutic strategy in the management of PCOS, especially in patients with altered metabolic profiles.